A vaccine to protect against cryptococcal infections
A subunit Cryptococcus vaccine
This study is working on a new vaccine to help prevent cryptococcosis, a serious fungal infection that can affect people with weakened immune systems, like those with HIV or who have had organ transplants, by testing different vaccine ingredients in mice to find the best way to boost the immune response before it’s tested in humans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-10842454 on NIH RePORTER |
What this research studies
This research focuses on developing a subunit vaccine aimed at preventing cryptococcosis, a serious infection caused by the fungi Cryptococcus neoformans and C. gattii, particularly in vulnerable populations such as those with HIV or organ transplant recipients. The researchers will conduct preclinical studies using mouse models to evaluate the effectiveness of various vaccine components and their ability to stimulate immune responses. By identifying specific protein antigens and combining them with a strong adjuvant, the goal is to create a vaccine that can be tested in humans in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are HIV-positive, organ transplant recipients, or residents of areas where cryptococcosis is common.
Not a fit: Patients who are not immunocompromised or do not live in endemic areas for cryptococcosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of cryptococcal meningitis in at-risk populations.
How similar studies have performed: While there have been various vaccine development efforts for cryptococcosis, this specific approach using a multiantigen subunit vaccine is relatively novel and has not been extensively tested in humans.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Levitz, Stuart Michael — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Levitz, Stuart Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.